Progyny, Inc. (PGNY) Form 8-K — Nov 4, 2026
Progyny (Nasdaq: PGNY) reported record Q3 2026 results with revenue of $341.3 million (+8.9% YoY), net income of $26.3 million ($0.32 diluted EPS vs $0.15 a year ago), and Adjusted EBITDA of $58.4 million. The company's most recent selling season delivered a record 1.3 million new covered lives and over 85 new clients, with near 100% retention for 2027, positioning the company to exceed 660 clients and roughly 8.3 million covered lives once new accounts go live.
Key figures
- Eps
- 0.32
- Revenue
- 341254000
- Guidance
- Full year 2026 revenue $1.365B-$1.385B (5.9%-7.5% growth); net income $107.0M-$110.6M ($1.30-$1.35/diluted share); Adjusted EBITDA $235.0M-$240.0M; Adjusted EPS $2.09-$2.13. Q4 2026: revenue $344.7M-$364.7M; net income $28.5M-$32.1M; Adjusted EBITDA $57.9M-$62.9M.
- Net Income
- 26252000
- Revenue Yoy
- 8.9%
- Total Assets
- 675793000
- Cash Position
- 195600000
- Shares Outstanding
- 74723072
- Clients
- 607 vs 553 a year ago
- Total debt
- no debt; $200M revolver undrawn
- Avg members
- 7176000
- Art cycles q3
- 16723
- Adjusted eps q3
- $0.52 vs $0.45 prior year
- Gross margin q3
- 24.5% vs 23.2% prior year
- Gross profit q3
- $83.7M, +15% YoY
- Adjusted ebitda q3
- $58.4M, +6.3% YoY
- Shares repurchased q3
- ~3 million shares for $82.7M
- Operating cash flow q3
- $56.6M vs $50.7M prior year
- Shares repurchased 2026
- ~11 million shares
- New covered lives season
- 1.3 million record
- Remaining buyback authorization
- ~$51 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.